Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma

Marker Therapeutics (MRKR) received a $2.6M FDA grant for a Phase 1 study of MT-601, its T cell therapy for pancreatic cancer. The company has prior funding and reported promising results in a Phase 1/2 study. MT-601 targets six tumor antigens and is also being tested for lymphoma. The pancreatic cancer study is set to begin in Q1 2027.

Evercore ISI upgraded Match Group (MTCH) to Outperform, raising its price target to $53 from $39. The upgrade is based on data indicating Tinder's user recovery is accelerating, tracking ahead of management's plan. MTCH stock is up 36% year-to-date at $42.95, with a current EV/EBITDA of 10.76. The company reported mixed Q2 results, exceeding profit expectations but slightly missing revenue projections. Analysts have varied ratings and price targets for the stock.

Biogen Inc. (BIIB) will present 76-week data on Empaveli and investigational drug felzartamab at the American Society of Nephrology Kidney Week. The data shows sustained proteinuria reduction and kidney function stabilization in patients with C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis. Empaveli's indication was recently expanded by the FDA. Felzartamab is being studied in multiple Phase 3 trials, with data expected in 2027.

ANI Pharmaceuticals (ANIP) launched Duloxetine Delayed-Release Capsules in 20, 30, and 60 mg, a generic version of Cymbalta. U.S. sales of this drug reached $247 million annually, according to August 2026 IQVIA data. The company aims to provide an alternative in a market with few competitors. ANIP shares closed at $72.29, up 0.01% on Nasdaq.

JPMorgan upgraded Intel (INTC) to Neutral from Underweight, citing balanced risk/reward as shares approach its $85 price target. Analyst Harlan Sur noted a 36% drop from June peak, with expected share losses in server CPUs. Intel's foundry revenue is $1B, far behind TSMC's $150B. Execution improved under CEO Lip Bu Tan, with positive EPS revisions expected. JPMorgan will monitor data center roadmaps and AI strategy.

Biogen Inc. will present 76-week data on EMPAVELI at the ASN conference, showing sustained proteinuria reduction and eGFR stabilization in kidney diseases. The company will also share updates on felzartamab, an investigational drug for immune-mediated kidney diseases. Biogen recently expanded EMPAVELI's U.S. label to include kidney function loss reduction.